Effects of Tongluo prescription on angiotensin level in plasma, kidney, heart and abdominal aorta in diabetic rats
Ying-xiang Song,Jun-jie Zou,Yong-quan Shi,Yan Liu,Liang-liang Sun,Wei Tang,Ming Liu,Zhi-min Liu
DOI: https://doi.org/10.3321/j.issn:1673-8225.2006.43.035
2006-01-01
Abstract:Aim: To observe the effects of Tongluo prescription on the levels of angiotensin I (Ang I) and angiotensin II (Ang II) in plasma, kidney, heart and abdominal aorta of experimental diabetic rats. Methods: The experiment was conducted in the Animal Center of the Shanghai Second Military Medical University of Chinese PLA from August to December 2005. A total of 30 male SD rats with the body mass ranged 160-200 g were selected. The rats were randomly divided into 2 groups after being fed for 5 days and fasted for 18 hours: Normal control group (n=10) and diabetic model group (n=20). Rats were induced to be diabetes with streptozotocin (STZ) (60 mg/kg by once abdominal injection). The blood glucose levels were measured three days after the injection to ensure a diabetic awe (≥ 16.7 mmol/L). Rats positive in diabetics were successful models, which were randomly divided into 2 groups after one-week feeding: Tongluo treatment group and non-treatment group with 10 rats in each group. Rats in the Tongluo treatment group were administrated by Tongluo prescription dissolved into the distilled water (10 g/kg per day), while rats in the non-treatment group and normal control group were given gastric perfusion of distilled water once at the same time and dose. At the 8th week, the levels of Ang I and II in plasma, kidney, heart and abdominal aorta were measured by radioimmunoassay. The difference was compared by single-factor analysis, and the differences among groups were compared with t test. Results: A total of 30 enrolled rats were involved in the analysis of results. 1 After eight weeks, the levels of Ang I and II in plasma, kidney, heart and abdominal aorta were significantly higher than those in the normal control grimp [Ang I (14.77±0.54), (10.31±0.37) μg/L; (5.65 ± 1.06), (3.73 ± 0.28) ng/kg; (3.99 ± 0.34), (2.72 ± 0.34) ng/ kg, (13.05 ± 1.29), (5.00 ± 0.29) ng/kg; Ang II (669.61 ± 38.15), (471.08 ± 23.47) ng/L; (6.36 ± 1.81), (2.64 ± 0.25) ng/kg; (3.84 ± 0.59), (2.49 ± 0.15) ng/kg; (12.52 ± 1.95), (4.37 ± 0.19) ng/kg; P < 0.01). 2 The levels of Ang I and II in plasma, kidney, heart and abdominal aorta were significantly lower after treated by Tongluo prescription than those in the non-treatment group, and the differences were remarkable [Ang I 12.81 ± 0.65) (14.77 ± 0.54) μg/L; (4.06 ± 0.46) (5.65 ± 1.06); (8.50 ± 1.15), (13.05 ± 1.29) ng/kg; (543.92 ± 30.80), (669.61 ± 38.15) ng/L; (3.58 ± 0.77), (6.36 ± 1.81); (8.54 ± 1.58), (12.52 ± 1.95) ng/kg; P<0.01). 3 The levels of Ang I and II in heart of all groups after treated by Tongluo prescription were lower than those in the non-treatment group, while the differences were not marked [(3.69 ± 0.67), (3.99 ± 0.34); (3.71 ± 1.05), (3.84 ± 0.59) ng/kg]. Conclusion: Tongluo prescription can decrease the levels of Ang I and Ang II in the plasma, kidney, heart and abdominal aorta of diabetic rats to different degree, and it maybe be beneficial to protect and postpone the development and progression of cardiovascular and renal disease in diabetes.